Package | Version | Identity | Name/Title | Status | FMM | WG | Date |
---|
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.199 | Trastuzumab Emtansine Injectable | active | | | 2021-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.200 | Gemtuzumab Ozogamicin Injectable | active | | | 2021-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.201 | Tagraxofusp Injectable | active | | | 2024-12 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.202 | Axicabtagene Ciloleucel Injectable | active | | | 2024-11 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.203 | BRCA1 | active | | | 2023-06 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.204 | BRCA2 | active | | | 2023-06 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.205 | BRCA1 Testing | active | | | 2023-06 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.207 | Epithelial Ovarian Cancer | active | | | 2024-08 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.208 | Primary Peritoneal Cancer | active | | | 2022-06 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.209 | Fallopian Tube Cancer | active | | | 2022-06 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.210 | Multigene Panel | active | | | 2023-07 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.211 | BRCA1 and BRCA2 | active | | | 2023-06 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.212 | BRCA1 and BRCA2 Testing | active | | | 2023-06 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.213 | BRAF V600 | active | | | 2022-01 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.214 | BRAF V600 Testing | active | | | 2023-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.215 | Colorectal Cancer | active | | | 2024-08 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.216 | BRAF V600 Mutation Status | active | | | 2022-01 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.217 | Cancer Stage I | active | | | 2024-08 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.218 | Head and Neck Cancer | active | | | 2022-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.219 | Malignant Melanoma of Skin | active | | | 2022-06 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.220 | Brain Cancer | active | | | 2022-07 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.221 | Waldenstrom Macroglobulinemia | active | | | 2024-08 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.222 | High Emetic Risk Intravenous Antineoplastic Agent | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.223 | Moderate Emetic Risk Intravenous Antineoplastic Agent | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.224 | Docetaxel Injectable | active | | | 2024-12 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.225 | Cyclophosphamide Injectable | active | | | 2022-09 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.226 | LAG 3 Inhibitor | active | | | 2024-11 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.233 | Chemotherapy Administration | active | | | 2024-01 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.240 | Pathological N Stage N3c | active | | | 2024-09 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.241 | Audio Visual Telehealth Encounter | active | | | 2025-01 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.242 | Moderate or High Emetic Risk Oral Antineoplastic Agent | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.243 | Minimal to Low Emetic Risk Oral Antineoplastic Agent | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.244 | Copanlisib Injectable | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.245 | Isatuximab Injectable | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.246 | Loncastuximab tesirine Injectable | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.247 | Margetuximab Injectable | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.248 | Mirvetuximab soravtansine Injectable | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.249 | Tafasitamab Injectable | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.250 | Teclistamab Injectable | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.251 | Tisotumab Injectable | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.252 | Asparaginase Injectable | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.254 | Belantamab Injectable | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.255 | Dostarlimab Injectable | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.256 | Mosunetuzumab Injectable | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.257 | Tremelimumab Injectable | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.258 | Indication for Dexamethasone | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.260 | Indication for Olanzapine | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.261 | Indication for Dexamethasone | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.263 | Indication for Olanzapine | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.264 | Prednisone | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.265 | As Needed PRN | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.3.266 | Amivantamab Injectable | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.200 | Doxorubicin | active | | | 2020-09 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.201 | Epirubicin | active | | | 2020-09 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.202 | Capecitabine | active | | | 2023-06 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.203 | Cyclophosphamide | active | | | 2020-09 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.204 | Injectable Fluorouracil | active | | | 2020-09 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.205 | Methotrexate | active | | | 2020-09 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.206 | Trastuzumab and Biosimilars | active | | | 2020-09 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.207 | HER2 Presence in Tissue | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.208 | Carboplatin | active | | | 2020-09 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.209 | Depression Screening for Adult | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.210 | Long Acting Opioids | active | | | 2020-10 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.211 | High Fiber Supplement or Diet Education | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.212 | Dexamethasone | active | | | 2021-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.213 | Olanzapine | active | | | 2021-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.214 | Pancreatic Cancer | active | | | 2020-10 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.215 | Audio Visual Telehealth Encounter | active | | | 2025-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.216 | Telephone Encounter | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.217 | Telehealth Emergency Department or Initial Inpatient | active | | | 2024-07 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.218 | Dyspnea Assessment | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.219 | Nausea or Vomiting Assessment | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.220 | Karnofsky Performance Status | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.221 | Referral to Hospice Care | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.222 | Referral to Palliative Care | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.223 | Palliative Care | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.224 | Enrollment in Hospice Care | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.225 | Advance Directive Including Durable Power of Attorney or Instructional | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.229 | Minimal Emetic Risk Intravenous Antineoplastic Agent | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.232 | Epithelial Ovarian Cancer | active | | | 2023-06 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.233 | Primary Peritoneal Cancer | active | | | 2022-06 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.235 | BRCA2 Testing | active | | | 2023-06 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.236 | Multigene Panel | active | | | 2023-07 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.237 | BRCA1 Testing | active | | | 2023-06 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.238 | First Line Drug Therapy for Metastatic Colorectal Cancer | active | | | 2022-01 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.239 | BRAF V600 Testing | active | | | 2022-01 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.240 | Cancer Stage 4 | active | | | 2022-01 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.241 | Cancer Stage M1 | active | | | 2024-12 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.242 | High Emetic Risk Intravenous Antineoplastic Agent | active | | | 2022-09 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.243 | Moderate Emetic Risk Intravenous Antineoplastic Agent | active | | | 2024-10 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.245 | Antiemetic Agent | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.247 | Indication for Dexamethasone | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.1444.5.249 | Indication for Olanzapine | active | | | 2025-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.2074.1.1.3 | Race Category Excluding Nulls | active | | | 2024-06 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.1002.77 | Codeine | active | | | 2024-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.1004.13 | Dihydrocodeine | active | | | 2024-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.1004.14 | Nalbuphine | active | | | 2020-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4009 | Malignant Intracranial Neoplasm | active | | | 2024-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4010 | Malignant Intracranial Neoplasm | active | | | 2023-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4015 | STEMI | active | | | 2022-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4016 | STEMI | active | | | 2019-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4017 | STEMI | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4019 | Fibrinolytic Therapy | active | | | 2023-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4023 | Cerebral Vascular Lesion | active | | | 2025-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4024 | Cerebral Vascular Lesion | active | | | 2025-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4025 | Cerebral Vascular Lesion | active | | | 2019-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4026 | Closed Head and Facial Trauma | active | | | 2019-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4028 | Aortic Dissection or Ruptured Aortic Aneurysm | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4029 | Acute Peptic Ulcer | active | | | 2023-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4030 | Acute Peptic Ulcer | active | | | 2023-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4031 | Acute Peptic Ulcer | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4032 | Dementia and Related Intracranial Pathologies | active | | | 2025-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4033 | Dementia and Related Intracranial Pathologies | active | | | 2025-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4034 | Active Bleeding or Bleeding Diathesis, Excluding Menses | active | | | 2025-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4035 | Active Bleeding or Bleeding Diathesis, Excluding Menses | active | | | 2022-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4036 | Active Bleeding or Bleeding Diathesis, Excluding Menses | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4043 | Dementia and Related Intracranial Pathologies | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4044 | Aortic Dissection or Ruptured Aortic Aneurysm | active | | | 2022-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4045 | Oral Anticoagulant Medications | active | | | 2023-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4046 | Cardiopulmonary Emergency | active | | | 2025-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4047 | Cardiopulmonary Emergency | active | | | 2025-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4048 | Cardiopulmonary Emergency | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4049 | Mechanical Circulatory Assist Device | active | | | 2024-07 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4050 | Mechanical Circulatory Assist Device | active | | | 2025-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4052 | Mechanical Circulatory Assist Device | active | | | 2025-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4053 | Pregnant State | active | | | 2022-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4054 | Pregnant State | active | | | 2024-07 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4055 | Pregnant State | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3157.4056 | Major Surgical Procedure | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3566.2.1005 | Chronic Stable Angina | active | | | 2024-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3566.2.1006 | Chronic Stable Angina | active | | | 2023-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.3566.3.1002 | Chronic Stable Angina | active | | | 2021-04 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1001 | Hospice Encounter | active | | | 2021-08 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1002 | Hospice Encounter | active | | | 2023-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1003 | Hospice Encounter | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1004 | Nutrition Services | active | | | 2021-09 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1005 | Nutrition Services | active | | | 2021-08 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1006 | Nutrition Services | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1007 | Hospice Care Ambulatory | active | | | 2021-08 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1008 | Hospice Care Ambulatory | active | | | 2021-08 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1005 | Office Visit | active | | | 2023-11 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1020 | Initial Hospital Inpatient Visit | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1030 | Discharge Services Hospital Inpatient Same Day Discharge | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1035 | Discharge Services Hospital Inpatient | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1040 | Outpatient Consultation | active | | | 2024-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1050 | Emergency Department Evaluation and Management Visit | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1060 | Nursing Facility Visit | active | | | 2024-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1065 | Discharge Services Nursing Facility | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1080 | Home Healthcare Services | active | | | 2024-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1110 | Preventive Care, Initial Office Visit, 0 to 17 | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1115 | Preventive Care Services Initial Office Visit, 18 and Up | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1120 | Preventive Care, Established Office Visit, 0 to 17 | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1125 | Preventive Care Services Established Office Visit, 18 and Up | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1130 | Preventive Care Services Individual Counseling | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1135 | Preventive Care Services Group Counseling | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1215 | Referral | active | | | 2023-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1216 | Face-to-Face Interaction | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1221 | Behavioral Health Follow up Visit | active | | | 2020-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1222 | Psychotherapy and Pharmacologic Management | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1228 | Detoxification Visit | active | | | 2021-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1232 | Audiology Visit | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1233 | Medical Disability Exam | active | | | 2019-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1260 | Telephone Visits | active | | | 2025-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1261 | Nursing Facility Visit | active | | | 2018-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1262 | Care Services in Long Term Residential Facility | active | | | 2018-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1264 | Office Visit | active | | | 2025-01 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1265 | Home Healthcare Services | active | | | 2021-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1266 | Outpatient Consultation | active | | | 2020-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1276 | Frailty Encounter | active | | | 2019-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1277 | Outpatient Encounter | active | | | 2025-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1278 | Outpatient Encounter | active | | | 2025-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1279 | Frailty Encounter | active | | | 2019-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1284 | Outpatient Encounter | active | | | 2023-11 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1285 | Palliative Encounter | active | | | 2025-01 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1286 | Palliative Encounter | active | | | 2024-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.11.1287 | Telephone Visits | active | | | 2021-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1001 | Office Visit | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1004 | Initial Hospital Inpatient Visit | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1006 | Discharge Services Hospital Inpatient Same Day Discharge | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1007 | Discharge Services Hospital Inpatient | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1008 | Outpatient Consultation | active | | | 2024-01 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1010 | Emergency Department Evaluation and Management Visit | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1012 | Nursing Facility Visit | active | | | 2024-01 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1013 | Discharge Services Nursing Facility | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1014 | Care Services in Long Term Residential Facility | active | | | 2024-02 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1016 | Home Healthcare Services | active | | | 2024-01 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1022 | Preventive Care Services, Initial Office Visit, 0 to 17 | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1023 | Preventive Care Services Initial Office Visit, 18 and Up | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1024 | Preventive Care, Established Office Visit, 0 to 17 | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1025 | Preventive Care Services Established Office Visit, 18 and Up | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1026 | Preventive Care Services Individual Counseling | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1027 | Preventive Care Services Group Counseling | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1046 | Referral | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1048 | Face-to-Face Interaction | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1054 | Behavioral Health Follow up Visit | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1055 | Psychotherapy and Pharmacologic Management | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1059 | Detoxification Visit | active | | | 2022-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1066 | Audiology Visit | active | | | 2017-05 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1073 | Medical Disability Exam | active | | | 2021-03 |
us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.101.12.1080 | Telephone Visits | active | | | 2025-02 |